Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Video Player

IFX-2.0 | Phase 3 Registration Trial

Upcoming Phase 3 Registration Trial Under Accelerated Approval

1st Line Keytruda® (pembrolizumab) With or Without Adjunctive IFx-2.0 for Advanced Merkel Cell

Enrolling ∼118 Patients

IFx-2.0 x3 weeks + Keytruda® vs Keytruda® + Placebo

20-25 US clinical centers

Randomized Placebo Controlled Phase 3 Trial

Primary Endpoint:

Overall Response Rate (ORR)

Key Secondary Endpoint:

Progression Free Survival (PFS)

We have worked with the FDA on a unique accelerated approval trial design which precludes the requirement to have at the time of BLA submission an ongoing trial to confirm clinical benefit for full approval. This trial will compare Overall Response Rates (ORR) achieved with Keytruda® (pembrolizumab), the current front line standard of care, to Keytruda® (pembrolizumab) plus adjunctive therapy with IFx-2.0.

Accelerated approval allows the use of a surrogate endpoint, like ORR, which is an endpoint likely to predict clinical benefit to bring the drug to patients with an unmet medical need sooner than using an endpoint known to have clinical benefit, like Progression Free or Overall Survival. Because ORR is a surrogate for clinical benefit, a Company is required to have ongoing at the time it submits an application for approval (BLA) a second trial designed to confirm clinical benefit.

Our accelerated approval trial utilizes dual step-wise endpoints, the primary endpoint for accelerated approval being ORR, results of which are analyzed within 6 months of the last patient enrolled in the trial. The study design also incorporates a key secondary endpoint of Progression Free Survival: an endpoint known to have clinical benefit. Progression Free Survival results may require 3 or more years after last patient enrolls in the study. As such, if successful in achieving the primary endpoint of ORR, IFx-2.0 could receive accelerated approval. If the key secondary endpoint of Progression Free Survival is achieved the accelerated approval would convert to full approval. This unique study design not only potentially accelerates the time to IFx-2.0 approval but also saves significant time and money by not being required to conduct a second trial to confirm the clinical benefit of IFx-2.0.

We expect to initiate this single registration directed trial under the FDA’s accelerated approval pathway for IFx-2.0 in the 2nd half of 2024. Enrollment is projected to take approximately 18 months, with top line results currently expected late 2025. The company anticipates conducting this trial under a Special Protocol Assessment Agreement (SPA) with the FDA. If successful, this trial would form the basis of a Biologics License Application (BLA) which the company would expect to submit to the FDA in mid 2026. The study population, dose, schedule, and study design are based on the response rates observed in the Company’s Phase 1b trial in patients with advanced Merkel cell carcinoma who exhibited primary resistance to anti PD(L)-1 checkpoint inhibitors such as Keytruda®.

[